Susvimo (ranibizumab) is not your average eye medicine. It is a prescription anti-VEGF treatment delivered through a tiny refillable ocular implant, designed for adults with certain long-term retinal diseases who have already shown they respond to anti-VEGF injections. Think of it as a medication “reservoir” for the eyenot a magic contact lens, not a bionic upgrade, and definitely not something you order online between socks and phone chargers.
Susvimo is used for neovascular, or wet, age-related macular degeneration (wet AMD), diabetic macular edema (DME), and diabetic retinopathy (DR) in patients who have previously responded to at least two intravitreal injections of a vascular endothelial growth factor inhibitor. That prior-response requirement matters because Susvimo is meant for people whose retina specialist already knows this drug class can help their eye disease.
This guide explains Susvimo uses, dosing, side effects, interactions, pictures and appearance, warnings, and real-world patient experience considerations. It is educational content only and should not replace advice from an ophthalmologist or retina specialist.
What Is Susvimo?
Susvimo is the brand name for ranibizumab injection 100 mg/mL for intravitreal use through the Susvimo ocular implant. Ranibizumab belongs to a group of medicines called VEGF inhibitors, or anti-VEGF drugs. VEGF stands for vascular endothelial growth factor, a protein involved in blood vessel growth and leakage.
In several retinal diseases, abnormal blood vessels may grow or leak fluid into the retina. That leakage can blur, distort, or damage central vision. Ranibizumab binds to VEGF-A and helps reduce abnormal vessel growth, leakage, and swelling. In plain English: it tells leaky, misbehaving blood vessels to calm down.
Unlike standard ranibizumab eye injections that are given directly into the eye at repeated visits, Susvimo uses a surgically placed implant that continuously releases medicine over time. The implant is refilled by a trained eye specialist at scheduled intervals.
What Is Susvimo Used For?
1. Wet Age-Related Macular Degeneration
Wet AMD is a serious eye condition in which abnormal blood vessels grow under the macula, the part of the retina responsible for sharp central vision. These vessels can leak blood or fluid, causing blurry vision, distorted lines, dark spots, or loss of central vision.
Susvimo may be used in adults with wet AMD who have already responded to at least two previous anti-VEGF injections. For some patients, the appeal is fewer routine eye injections while still maintaining consistent anti-VEGF therapy.
2. Diabetic Macular Edema
Diabetic macular edema happens when diabetes-related damage causes retinal blood vessels to leak fluid into the macula. The result can be swelling, blurry vision, muted colors, and trouble reading or recognizing faces.
Susvimo is approved for DME in adults who previously responded to anti-VEGF injections. It may be considered when a retina specialist believes long-acting continuous delivery is appropriate.
3. Diabetic Retinopathy
Diabetic retinopathy is caused by damage to retinal blood vessels from diabetes. It can progress quietly, which is rude but common for eye disease. Some people have no symptoms until the condition becomes advanced.
For adults with diabetic retinopathy who have responded to previous anti-VEGF therapy, Susvimo may help manage disease activity with a longer refill schedule than wet AMD or DME.
How Susvimo Works
Susvimo works by continuously releasing ranibizumab into the vitreous, the gel-like part inside the eye. Ranibizumab blocks VEGF-A, helping reduce the abnormal blood vessel growth and leakage that contribute to wet AMD, DME, and diabetic retinopathy.
The big difference is delivery. Instead of receiving frequent injections into the eye, the patient has an implant placed during a surgical procedure. The implant is then refilled during office-based or procedure-based visits using a special refill needle. Your eye doctor still monitors your retina with exams and imaging, because even high-tech implants appreciate supervision.
Susvimo Dosing and Refill Schedule
The recommended Susvimo dose is 2 mg of ranibizumab, delivered continuously through the ocular implant.
For Wet AMD and DME
For neovascular wet AMD and diabetic macular edema, Susvimo is typically refilled every 24 weeks, or about every six months.
For Diabetic Retinopathy
For diabetic retinopathy, Susvimo is typically refilled every 36 weeks, or about every nine months.
Supplemental Treatment
Some patients may still need supplemental intravitreal ranibizumab treatment if the retina specialist determines it is medically necessary before the next refill. In other words, Susvimo can reduce treatment burden for selected patients, but it does not mean you can ghost your retina clinic.
How Susvimo Is Given
Susvimo is not swallowed, rubbed on the eyelid, or dropped into the eye. It is used through an ocular implant. The implant is surgically inserted into the eye by a physician experienced in vitreoretinal surgery, usually in an operating room or appropriate surgical setting under sterile conditions.
After the implant is placed, follow-up visits are essential. The eye doctor checks the implant site, retina, vision, eye pressure, and any symptoms. Refills are performed using strict aseptic technique to reduce infection risk.
Patients should follow all post-procedure instructions carefully. That may include using prescribed eye drops, avoiding certain activities for a period of time, wearing an eye shield if instructed, and calling the clinic immediately if warning symptoms appear.
What Does Susvimo Look Like? Pictures and Appearance
Susvimo is supplied as a sterile solution in a single-dose vial. The liquid is described as clear to slightly opalescent and colorless to slightly brownish. The implant itself is a small refillable device designed for placement in the eye, where it is not something patients casually inspect in the bathroom mirror.
If you are looking for Susvimo pictures, official medication guides and prescribing materials may show the vial, implant, needles, and procedural diagrams. These images are intended for education and professional use. They are not a do-it-yourself manual. Eye surgery is firmly in the “please let trained professionals handle this” category.
Common Susvimo Side Effects
Common side effects reported with Susvimo may include:
- Blood on the white part of the eye
- Eye redness
- Eye pain or discomfort
- Sensitivity to light
- Inflammation inside the eye
- Vitreous floaters
- Cataract
- Temporary decrease in vision after the implant procedure
Some eye redness or irritation can happen after eye procedures, but patients should never assume symptoms are “normal” if they are worsening, intense, or paired with vision changes. Eyes are tiny organs with dramatic personalities; when they complain loudly, listen.
Serious Side Effects and Boxed Warning
Susvimo carries a boxed warning for endophthalmitis, a serious infection inside the eye. This infection can cause permanent eye damage, including severe vision loss or blindness, and requires urgent medical or surgical treatment.
Call your eye doctor right away or seek urgent care if you notice:
- Increasing eye pain
- Sudden or worsening vision loss
- Light sensitivity
- Increasing redness in the white of the eye
- Eye discharge
- A new feeling that something is stuck in the eye
- New flashes, many new floaters, or a curtain-like shadow
Other serious implant-related risks include retinal detachment, implant dislocation, septum dislodgement, vitreous hemorrhage, conjunctival erosion, conjunctival retraction, conjunctival bleb, and postoperative inflammation. Some of these may require surgery.
Who Should Not Use Susvimo?
Susvimo is not appropriate for everyone. It is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to ranibizumab products or any ingredients in Susvimo.
Your doctor also needs to know about your full eye history, including prior eye surgeries, retinal tears or detachments, glaucoma, inflammation, infections, bleeding problems, or use of blood thinners. The more your retina specialist knows, the better they can decide whether Susvimo is a smart choice or a complication looking for a calendar invite.
Susvimo Interactions
Susvimo does not have the kind of everyday food interactions people ask about with pills. Grapefruit is not the villain here. However, medication history still matters.
Patients taking antithrombotic medicines, such as aspirin, nonsteroidal anti-inflammatory drugs, antiplatelet drugs, or anticoagulants, may have an increased risk of vitreous hemorrhage around the implant procedure. Doctors may recommend temporarily interrupting certain medicines before surgery, but patients should never stop blood thinners on their own. That decision must be coordinated with the prescribing clinician.
Tell your eye doctor about all prescription drugs, over-the-counter medicines, vitamins, supplements, and eye drops you use. Also mention any recent eye injections or planned eye procedures.
Pregnancy, Breastfeeding, and Fertility Considerations
People who are pregnant, planning pregnancy, or breastfeeding should discuss the risks and benefits of Susvimo with their healthcare provider. Anti-VEGF therapy may pose risks based on how the drug works, and the prescribing information recommends effective contraception for females of reproductive potential during treatment and for a period after the last dose.
There are limited data on ranibizumab in human milk. A healthcare professional can help weigh the need for treatment against possible risks to a breastfed child.
What to Expect Before and After the Procedure
Before the Implant
Before Susvimo, patients usually undergo retinal imaging, visual acuity testing, and a review of prior anti-VEGF response. The doctor confirms that the eye condition fits the approved indication and that the patient is a reasonable surgical candidate.
During the Procedure
The implant procedure is performed under sterile conditions. The eye is numbed, prepared with antiseptic, and the implant is inserted by a trained vitreoretinal surgeon. Patients should not expect to watch the process like a cooking show; the goal is safety, precision, and zero unnecessary drama.
After the Procedure
Temporary vision decrease can occur after implantation, especially in the first month or two. Patients need follow-up visits to monitor healing, eye pressure, inflammation, implant position, and retinal disease activity.
Susvimo vs Regular Eye Injections
Standard anti-VEGF injections are often given repeatedly, sometimes monthly or on individualized schedules. Susvimo was developed to reduce the frequency of treatment visits for selected patients by providing continuous ranibizumab delivery.
The tradeoff is that Susvimo involves surgery and implant-related risks. Regular injections involve repeated needle procedures but do not require a permanent refillable implant. The better option depends on disease activity, treatment response, eye anatomy, safety risks, lifestyle, and patient preference.
Practical Patient Experience: Living With Susvimo
For many patients, the hardest part of chronic retinal disease is not one single appointment. It is the repetition. The calendar fills with eye exams, scans, injections, rides home, pharmacy questions, insurance paperwork, and the recurring thought: “Again?” Susvimo may appeal to people who have responded well to anti-VEGF therapy but struggle with frequent injection schedules.
A typical patient experience begins before the implant is even discussed. Someone with wet AMD may have already received several eye injections and noticed that vision stabilizes when treatment stays on track. A person with DME may have learned that blood sugar control, blood pressure, and eye appointments all work together like a group project where everyone actually needs to participate. A patient with diabetic retinopathy may not feel symptoms every day, yet imaging shows disease activity that needs treatment.
The first practical question is usually transportation. After an implant procedure, patients may need someone to drive them home. They may also need help with errands, reading medication instructions, or remembering eye-drop schedules. This is not weakness; it is logistics. Even superheroes would probably ask for a ride after eye surgery.
The second experience issue is anxiety. Eye procedures can sound intimidating. Many patients worry about pain, vision changes, or what the implant will feel like. A good retina clinic explains the steps clearly, reviews warning signs, and gives written instructions. Patients should ask questions such as: How long should I avoid strenuous activity? What symptoms are urgent? Whom do I call after hours? When is my next refill? Can I travel before my follow-up visit?
The third issue is monitoring. Susvimo may reduce treatment frequency, but it does not eliminate follow-up. Patients still need retinal imaging and eye exams. Vision can change between visits, and diabetic eye disease can progress even when the patient feels fine. Keeping appointments is part of the treatment, not optional decoration.
Daily life after Susvimo often becomes a rhythm. Patients may track vision with an Amsler grid if recommended, keep diabetes and blood pressure under control, protect eyes from injury, and report symptoms quickly. The most successful patients are usually not the ones who memorize every medical term. They are the ones who notice changes, communicate early, and do not wait three weeks hoping eye pain will “walk it off.”
There is also an emotional side. Vision problems can make reading, driving, hobbies, work, and independence feel uncertain. A longer-acting treatment can offer relief for some people, but it may also bring new concerns about implant safety. Honest conversations with the retina specialist help patients understand the benefit-risk balance in their own situation.
One helpful mindset is to see Susvimo as a treatment partnership. The implant delivers medicine continuously, the doctor monitors the eye, and the patient reports symptoms and keeps appointments. When all three do their jobs, the plan has a much better chance of working smoothly.
Conclusion
Susvimo (ranibizumab) is a prescription anti-VEGF treatment delivered through a refillable ocular implant for adults with wet AMD, diabetic macular edema, or diabetic retinopathy who have already responded to previous anti-VEGF injections. Its main advantage is reduced treatment frequency for selected patients, with refills every six months for wet AMD and DME and every nine months for diabetic retinopathy.
However, Susvimo is not simply a “fewer appointments” shortcut. It involves eye surgery, careful follow-up, and serious potential risks, including endophthalmitis, retinal detachment, vitreous hemorrhage, implant dislocation, and conjunctival complications. Patients should discuss their medical history, eye history, medication list, and personal treatment goals with a retina specialist before deciding whether Susvimo is right for them.
Medical note: This article is for educational purposes only. Susvimo dosing, suitability, and safety decisions must be made by a qualified eye care professional based on the individual patient’s condition.
